TXG241220C50000
- 0.10
- 0.000.00%
10x Genomics Newsroom
Bruker to Seek Injunction, Appeal After Court Sides With 10x Genomics in Patent Dispute
Bruker Plans to File for a Stay of NanoString GeoMX Injunction Ruling
10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US
10x Genomics: Injunction Expected to Prohibit Bruker From Making, Using, Selling or Offering to Sell in U.S. GeoMx Digital Spatial Profiler and Associated Instruments, Reagents and Services for RNA and Protein Detection >BRKR
Reported Earlier, Delaware Jury Awards 10x Genomics $31.7M In Patent Case Against NanoString; Permanent Injunction On GeoMx Takes Effect January 10, 2025, With Royalties For Existing Installations; Additional Rulings On CosMx Expected Spring 2025
Worst Performing Stocks for Tax Loss Selling – Wolfe
10x Genomics (NASDAQ:TXG Investor Three-year Losses Grow to 89% as the Stock Sheds US$73m This Past Week
Trump's Unusual Pick for NIH Director May Be a Win for These Stocks -- Barrons.com
10x Banking and Alloy Partner to Bring Cloud-native Risk Decisioning to Financial Services
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com
10x Genomics, Inc. (TXG): Among the Best Genomics Stocks to Buy Right Now
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
ARKK's Holdings Ranked by SA Quant Grades
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
10x Genomics Is Maintained at Overweight by Barclays
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $14 to $30